HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Open in Screener

HLXC

Helix Acquisition Corp III

Last Close
Feb 26  •  04:00PM ET
10.24
Dollar change
-0.06
Percentage change
-0.58 %
Financial • Shell Companies • USA • NASD
Index- P/E- EPS (ttm)- Insider Own16.87% Shs Outstand19.79M Perf Week-0.10%
Market Cap44.16M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float16.45M Perf Month-0.10%
Enterprise Value- PEG- EPS next Q- Inst Own11.87% Short Float0.01% Perf Quarter-
Income- P/S- EPS this Y- Inst Trans- Short Ratio0.01 Perf Half Y-
Sales- P/B- EPS next Y- ROA- Short Interest0.00M Perf YTD-0.10%
Book/sh- P/C- EPS next 5Y- ROE- 52W High10.35 -1.11% Perf Year-
Cash/sh- P/FCF- EPS past 3/5Y- - ROIC- 52W Low10.13 1.09% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility0.78% 0.73% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)0.08 Perf 10Y-
Dividend Ex-Date- Quick Ratio- Sales Y/Y TTM- Profit Margin- RSI (14)49.26 Recom-
Dividend Gr. 3/5Y- - Current Ratio- EPS Q/Q- SMA200.21% Beta- Target Price-
Payout- Debt/Eq- Sales Q/Q- SMA500.18% Rel Volume0.03 Prev Close10.30
Employees3 LT Debt/Eq- Earnings- SMA2000.18% Avg Volume302.87K Price10.24
IPOJan 23, 2026 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume10,460 Change-0.58%
Jan-27-26 07:30AM
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares
(GlobeNewswire)
Jan-23-26 07:30AM
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering
(GlobeNewswire)
Helix Acquisition Corp. III operates as blank check company. The company was founded on September 10, 2025 and is headquartered in Boston. MA.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

MLTX

MoonLake Immunotherapeutics

Last Close
Feb 26  •  04:00PM ET
17.68
Dollar change
-0.54
Percentage change
-2.96 %
Healthcare • Biotechnology • Switzerland • NASD
MLTX MoonLake Immunotherapeutics daily Stock Chart
Peers: AMGN VRTX REGN ALNY BIIB BMRN GILD INCY SRPT BLUE
 | Held by: ESML VHT SBIO NUSC ONEQ VT BBC FHLC TMED ESGV
Index- P/E- EPS (ttm)-3.53 Insider Own12.29% Shs Outstand71.37M Perf Week-2.70%
Market Cap1.25B Forward P/E- EPS next Y-3.78 Insider Trans-44.18% Shs Float62.14M Perf Month8.80%
Enterprise Value934.32M PEG- EPS next Q-0.89 Inst Own78.48% Short Float11.70% Perf Quarter34.45%
Income-227.32M P/S- EPS this Y1.31% Inst Trans25.78% Short Ratio3.28 Perf Half Y-67.56%
Sales0.00M P/B4.14 EPS next Y-7.93% ROA-50.38% Short Interest7.27M Perf YTD34.14%
Book/sh4.27 P/C3.18 EPS next 5Y11.82% ROE-60.51% 52W High62.75 -71.82% Perf Year-58.27%
Cash/sh5.56 P/FCF- EPS past 3/5Y-27.48% -256.78% ROIC-59.99% 52W Low5.95 197.14% Perf 3Y-1.78%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.03% 5.91% Perf 5Y60.73%
Dividend TTM- EV/Sales- EPS Y/Y TTM-86.55% Oper. Margin- ATR (14)1.05 Perf 10Y-
Dividend Ex-Date- Quick Ratio9.27 Sales Y/Y TTM- Profit Margin- RSI (14)58.23 Recom1.86
Dividend Gr. 3/5Y- - Current Ratio9.27 EPS Q/Q-27.40% SMA206.32% Beta1.20 Target Price27.08
Payout- Debt/Eq0.25 Sales Q/Q- SMA5014.08% Rel Volume0.39 Prev Close18.22
Employees130 LT Debt/Eq0.24 EarningsFeb 22 AMC SMA200-42.56% Avg Volume2.22M Price17.68
IPOOct 20, 2020 Option/ShortYes / Yes EPS/Sales Surpr.4.26% - Trades Volume906,342 Change-2.96%
Date Action Analyst Rating Change Price Target Change
Jan-15-26Downgrade Goldman Neutral → Sell $10
Jan-09-26Upgrade BTIG Research Neutral → Buy $24
Nov-03-25Upgrade H.C. Wainwright Neutral → Buy $30
Oct-02-25Downgrade H.C. Wainwright Buy → Neutral
Oct-01-25Downgrade Goldman Buy → Neutral $7
Sep-30-25Downgrade Wolfe Research Outperform → Underperform $2
Sep-30-25Downgrade Citigroup Buy → Neutral $5
Sep-29-25Downgrade Stifel Buy → Hold $13
Sep-29-25Downgrade RBC Capital Mkts Outperform → Sector Perform $10
Sep-29-25Downgrade Jefferies Buy → Hold $8
Show Previous Ratings
Feb-24-26 01:16AM
MoonLake Immunotherapeutics Investor Day: HS BLA on Track, axSpA Phase 2 Data Highlights Imaging Wins
(MarketBeat)
Feb-23-26 09:10AM
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
(Benzinga)
Feb-22-26 11:00AM
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
(GlobeNewswire)
Feb-03-26 03:48PM
BioTech Breakout: MoonLake Up 30% On FDA Wins
(MarketBeat)
Feb-02-26 02:25PM
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
(Benzinga)
09:36AM Loading…
09:36AM
Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play
(Insider Monkey)
08:00AM
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
(GlobeNewswire)
Jan-15-26 04:33PM
Stocks Boosted by Chip Demand Optimism
(Barchart) -6.09%
Jan-09-26 06:28AM
Insmeds ginormous lung drug sales; J&Js US pricing deal
(BioPharma Dive) +28.94%
Jan-08-26 02:06PM
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars
(Benzinga) +27.02%
10:19AM
MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug
(Investor's Business Daily)
08:00AM
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
(GlobeNewswire)
Dec-15-25 12:00PM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX
(Business Wire)
Dec-11-25 08:01AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
(PR Newswire)
Dec-09-25 09:00AM
Investors in MoonLake Immunotherapeutics Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
(PR Newswire)
02:26AM Loading…
Dec-08-25 02:26AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
(PR Newswire)
Dec-03-25 03:05PM
MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman
(PR Newswire) +6.63%
Dec-02-25 09:00AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
(PR Newswire) -5.51%
Dec-01-25 08:38PM
MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority
(PR Newswire)
03:18PM
MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15
(Newsfile)
04:25AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
(PR Newswire)
Nov-27-25 02:16PM
MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
(Newsfile)
Nov-26-25 08:50AM
MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman
(PR Newswire)
Nov-25-25 04:31PM
MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
(PR Newswire)
Nov-21-25 08:45AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MLTX
(PR Newswire)
Nov-14-25 09:00AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
(PR Newswire)
Nov-11-25 04:25AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
(PR Newswire) +8.60%
Nov-07-25 02:49AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
(PR Newswire)
Nov-05-25 07:11AM
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
(GlobeNewswire)
07:00AM
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab
(GlobeNewswire)
08:46AM Loading…
Oct-29-25 08:46AM
MLTX STOCK LOSS NOTICE: MoonLake Immunotherapeutics Investors are Notified they may have been Affected by Fraud and are Urged to Contact BFA Law
(Newsfile)
Oct-28-25 08:55AM
Investors in MoonLake Immunotherapeutics (MLTX): Protect Your Rights - Contact Levi & Korsinsky Before December 15, 2025
(Newsfile)
Oct-22-25 05:47PM
The Best AI for Picking Stocks, Ranked by Performance
(MarketBeat)
Oct-16-25 03:14AM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
(PR Newswire) -5.16%
Oct-15-25 03:41PM
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX
(Business Wire)
Oct-14-25 12:03PM
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman
(PR Newswire)
Oct-01-25 08:12AM
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman
(PR Newswire)
Sep-29-25 05:30PM
Podcast: U.S. Stocks Tick Higher as Government Shutdown Looms
(The Wall Street Journal) -89.93% +14.81%
11:46AM
Applovin, furniture stocks, MoonLake: Trending Tickers
(Yahoo Finance Video)
09:42AM
UCB Soars to Record as Rival MoonLake Crashes on Trial Data
(Bloomberg)
09:38AM
MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment
(Investor's Business Daily)
08:40AM
MoonLake Immunotherapeutics Stock Collapses. Why It's Down 88%.
(Barrons.com)
Sep-28-25 12:04PM
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab
(GlobeNewswire)
Sep-10-25 12:59AM
Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)
(Insider Monkey)
Aug-27-25 03:32AM
2 Small-Cap Biotech Stocks Well Positioned for a Breakout
(Motley Fool)
Aug-16-25 10:41PM
MoonLake Immunotherapeutics (MLTX): A Bull Case Theory
(Insider Monkey)
Aug-05-25 07:00AM
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
(GlobeNewswire)
Jul-31-25 12:33PM
Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment
(Insider Monkey)
Jul-09-25 01:09AM
Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports
(Reuters)
Jun-04-25 12:06PM
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
(Zacks) +5.15%
Jun-03-25 09:33AM
Constellation and Meta, Merck, Snowflake: Trending Tickers
(Yahoo Finance Video) +17.95%
09:32AM
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
(Investor's Business Daily)
09:27AM
MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid
(Investor's Business Daily)
07:38AM
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
(Benzinga)
07:20AM
MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win.
(Barrons.com)
Jun-02-25 05:08PM
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
(Reuters) +5.51%
May-27-25 03:33PM
H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT
(Insider Monkey)
May-15-25 09:55AM
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
(Zacks)
May-12-25 04:00PM
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
(GlobeNewswire)
Apr-25-25 04:05PM
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
(GlobeNewswire)
Apr-23-25 12:52PM
Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
(Insider Monkey)
Apr-08-25 03:31AM
MoonLake Immunotherapeutics: A Buy At Dips
(Seeking Alpha) -5.59%
Apr-03-25 07:00AM
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
(GlobeNewswire)
Feb-26-25 07:00AM
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
(GlobeNewswire)
Feb-25-25 09:49AM
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?
(Insider Monkey)
Feb-23-25 01:33PM
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts
(Insider Monkey)
Feb-20-25 12:12PM
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now
(Insider Monkey)
Jan-10-25 07:15AM
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
(TipRanks)
Jan-08-25 07:00AM
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab
(GlobeNewswire)
Nov-13-24 08:00AM
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis
(GlobeNewswire)
Nov-07-24 07:00AM
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
(GlobeNewswire)
Oct-08-24 09:11PM
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics
(GuruFocus.com)
Sep-24-24 11:55PM
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
(Insider Monkey) -6.36%
Sep-23-24 02:44AM
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
(Insider Monkey)
Sep-09-24 07:00AM
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
(GlobeNewswire)
Aug-27-24 08:21PM
MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months
(Insider Monkey)
Aug-07-24 08:00AM
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
(GlobeNewswire)
Jun-10-24 08:00AM
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis
(GlobeNewswire)
May-16-24 08:00AM
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
(GlobeNewswire)
May-07-24 09:02PM
MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
(GuruFocus.com)
01:53PM
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
(InvestorPlace)
10:15AM
MoonLake Immunotherapeutics Q1 Net Loss Widens
(MT Newswires)
08:00AM
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
(GlobeNewswire)
Apr-10-24 07:00AM
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
(GlobeNewswire)
Mar-11-24 04:25PM
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
(Investor's Business Daily)
Mar-10-24 12:00PM
MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
(GlobeNewswire)
Mar-04-24 08:00AM
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
(GlobeNewswire)
Mar-01-24 12:38AM
Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)
(GuruFocus.com) +5.56%
Feb-29-24 08:00AM
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
(GlobeNewswire) -15.09%
Feb-26-24 08:00AM
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
(GlobeNewswire)
Feb-20-24 11:44PM
Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics
(GuruFocus.com) -7.88%
Jan-11-24 09:55AM
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
(Zacks)
Jan-10-24 08:42AM
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
(Zacks)
Dec-22-23 03:01PM
CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics
(GuruFocus.com)
Nov-14-23 12:13PM
MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses
(GuruFocus.com)
08:00AM
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
(GlobeNewswire)
Nov-06-23 04:03PM
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
(Investor's Business Daily) -29.11% +15.98%
09:46AM
Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug
(Investor's Business Daily)
Nov-05-23 11:00AM
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis
(GlobeNewswire)
Oct-26-23 10:33AM
12 Best Performing NASDAQ Stocks in 2023
(Insider Monkey)
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Santos da Silva JorgeChief Executive OfficerDec 08 '25Sale15.08130,0001,960,4002,948,577Dec 10 04:29 PM
Santos da Silva JorgeChief Executive OfficerDec 09 '25Sale14.4970,0001,014,3002,878,577Dec 10 04:29 PM
Reich KristianChief Scientific OfficerDec 08 '25Sale15.08130,0001,960,40072,908Dec 10 04:29 PM
Reich KristianChief Scientific OfficerDec 09 '25Sale14.4372,9081,052,0620Dec 10 04:29 PM
Jorge Pedro Santos Radeck Da SOfficerDec 08 '25Proposed Sale14.90200,0002,980,000Dec 08 10:36 AM
Kristian Dieter Johannes ReichOfficerDec 08 '25Proposed Sale14.80202,9083,003,038Dec 08 10:07 AM
Bodenstedt MatthiasChief Financial OfficerOct 08 '25Buy9.0910,87098,808627,536Oct 09 09:01 AM
Chen BihuaFormer 10% OwnerSep 29 '25Sale7.216,494,15146,827,6282,000,000Oct 01 05:22 PM
Chen BihuaFormer 10% OwnerSep 30 '25Sale6.965,82740,5561,994,173Oct 01 05:22 PM
Moukheibir CatherineDirectorJul 03 '25Option Exercise0.0023,500023,500Jul 07 04:03 PM
Moukheibir CatherineDirectorJul 03 '25Sale48.7923,5001,146,5650Jul 07 04:03 PM
Moukheibir CatherineDirectorJul 03 '25Proposed Sale48.7923,5001,146,595Jul 03 01:23 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.